• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

XEC变体:基因组进化、免疫逃逸及对公共卫生的影响

The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications.

作者信息

Aljabali Alaa A A, Lundstrom Kenneth, Hromić-Jahjefendić Altijana, El-Baky Nawal Abd, Nawn Debaleena, Hassan Sk Sarif, Rubio-Casillas Alberto, Redwan Elrashdy M, Uversky Vladimir N

机构信息

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.

PanTherapeutics, Rte de Lavaux 49, CH1095 Lutry, Switzerland.

出版信息

Viruses. 2025 Jul 15;17(7):985. doi: 10.3390/v17070985.

DOI:10.3390/v17070985
PMID:40733602
Abstract

Narrative review synthesizes the most current literature on the SARS-CoV-2 XEC variant, focusing on its genomic evolution, immune evasion characteristics, epidemiological dynamics, and public health implications. To achieve this, we conducted a structured search of the literature of peer-reviewed articles, preprints, and official surveillance data from 2023 to early 2025, prioritizing virological, clinical, and immunological reports related to XEC and its parent lineages. Defined by the distinctive spike protein mutations, T22N and Q493E, XEC exhibits modest reductions in neutralization in vitro, although current evidence suggests that mRNA booster vaccines, including those targeting JN.1 and KP.2, retain cross-protective efficacy against symptomatic and severe disease. The XEC strain of SARS-CoV-2 has drawn particular attention due to its increasing prevalence in multiple regions and its potential to displace other Omicron subvariants, although direct evidence of enhanced replicative fitness is currently lacking. Preliminary analyses also indicated that glycosylation changes at the N-terminal domain enhance infectivity and immunological evasion, which is expected to underpin the increasing prevalence of XEC. The XEC variant, while still emerging, is marked by a unique recombination pattern and a set of spike protein mutations (T22N and Q493E) that collectively demonstrate increased immune evasion potential and epidemiological expansion across Europe and North America. Current evidence does not conclusively associate XEC with greater disease severity, although additional research is required to determine its clinical relevance. Key knowledge gaps include the precise role of recombination events in XEC evolution and the duration of cross-protective T-cell responses. New research priorities include genomic surveillance in undersampled regions, updated vaccine formulations against novel spike epitopes, and long-term longitudinal studies to monitor post-acute sequelae. These efforts can be augmented by computational modeling and the One Health approach, which combines human and veterinary sciences. Recent computational findings (GISAID, 2024) point to the potential of XEC for further mutations in under-surveilled reservoirs, enhancing containment challenges and risks. Addressing the potential risks associated with the XEC variant is expected to benefit from interdisciplinary coordination, particularly in regions where genomic surveillance indicates a measurable increase in prevalence.

摘要

叙述性综述综合了关于SARS-CoV-2 XEC变体的最新文献,重点关注其基因组进化、免疫逃逸特征、流行病学动态以及对公共卫生的影响。为此,我们对2023年至2025年初的同行评审文章、预印本和官方监测数据进行了结构化检索,优先考虑与XEC及其亲本谱系相关的病毒学、临床和免疫学报告。XEC由独特的刺突蛋白突变T22N和Q493E定义,尽管目前的证据表明包括针对JN.1和KP.2的mRNA加强疫苗对有症状和严重疾病仍具有交叉保护效力,但XEC在体外的中和作用略有降低。SARS-CoV-2的XEC毒株因其在多个地区的流行率不断上升以及取代其他奥密克戎亚变体的潜力而受到特别关注,尽管目前缺乏其复制适应性增强的直接证据。初步分析还表明,N端结构域的糖基化变化增强了感染性和免疫逃逸能力,这有望解释XEC流行率上升的原因。XEC变体仍在出现,其特点是独特的重组模式和一组刺突蛋白突变(T22N和Q493E),这些突变共同显示出在欧洲和北美的免疫逃逸潜力增加和流行病学传播范围扩大。目前的证据并未确凿地将XEC与更高的疾病严重程度联系起来,尽管还需要进一步研究来确定其临床相关性。关键的知识空白包括重组事件在XEC进化中的精确作用以及交叉保护性T细胞反应的持续时间。新的研究重点包括在采样不足地区进行基因组监测、针对新的刺突表位更新疫苗配方以及监测急性后遗症的长期纵向研究。计算建模和“同一个健康”方法(将人类和兽医学科结合起来)可以加强这些努力。最近的计算结果(全球流感共享数据库,2024年)表明,XEC在监测不足的宿主中有进一步突变的潜力,这增加了控制的挑战和风险。应对与XEC变体相关的潜在风险预计将受益于跨学科协调,特别是在基因组监测表明流行率有可测量增加的地区。

相似文献

1
The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications.XEC变体:基因组进化、免疫逃逸及对公共卫生的影响
Viruses. 2025 Jul 15;17(7):985. doi: 10.3390/v17070985.
2
Genetic and Immunological Profiling of Recent SARS-CoV-2 Omicron Subvariants: Insights into Immune Evasion and Infectivity in Monoinfections and Coinfections.新冠病毒奥密克戎变种新亚型的基因和免疫特征分析:单重感染和合并感染中免疫逃逸及传染性的见解
Viruses. 2025 Jun 27;17(7):918. doi: 10.3390/v17070918.
3
Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.新型冠状病毒XEC变异株N端结构域糖基化突变在免疫逃逸、细胞间融合及刺突蛋白稳定性中的作用
J Virol. 2025 Apr 15;99(4):e0024225. doi: 10.1128/jvi.00242-25. Epub 2025 Mar 26.
4
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
5
Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)亚变体KP.3.1.1和XEC的抗体逃避性
Cell Rep. 2025 Apr 22;44(4):115543. doi: 10.1016/j.celrep.2025.115543. Epub 2025 Apr 8.
6
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.针对 COVID-19 的一种改良信使核糖核酸-脂质纳米颗粒候选疫苗的安全性和免疫原性:一项 1 期、剂量递增研究的结果。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2408863. doi: 10.1080/21645515.2024.2408863. Epub 2024 Oct 18.
7
Nanopore sequencing reveals the genomic diversity of the variants of concern of SARS-CoV-2 during 2021 disease outbreak in Pakistan.纳米孔测序揭示了2021年巴基斯坦疾病爆发期间新冠病毒变异株的基因组多样性。
Sci Rep. 2025 Aug 1;15(1):28129. doi: 10.1038/s41598-025-12774-1.
8
Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant.新型冠状病毒JN.1变体的免疫逃逸、传染性和膜融合
Virol J. 2025 May 24;22(1):162. doi: 10.1186/s12985-025-02737-3.
9
Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history.具有不同疫苗接种史的小鼠中,单价和多价亚单位疫苗针对新冠病毒变异株的免疫原性。
Microbiol Spectr. 2025 Jul 17:e0290724. doi: 10.1128/spectrum.02907-24.
10
The spike 486 site is a key immune evasion point and a determinant of the immunogenicity of the RBD-dimer mRNA vaccine against SARS-CoV-2 variants.刺突蛋白486位点是关键的免疫逃逸点,也是RBD二聚体mRNA疫苗针对新冠病毒变异株免疫原性的决定因素。
Virology. 2025 Jun 20;610:110612. doi: 10.1016/j.virol.2025.110612.

引用本文的文献

1
Emerging SARS-CoV-2 variants: genomic shifts, immune evasion, and therapeutic perspectives.新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体:基因组变化、免疫逃逸及治疗前景
Mol Biol Rep. 2025 Sep 10;52(1):886. doi: 10.1007/s11033-025-11009-w.

本文引用的文献

1
Optimizing a human monoclonal antibody for better neutralization of SARS-CoV-2.优化一种人类单克隆抗体以更好地中和新型冠状病毒。
Nat Commun. 2025 Jul 4;16(1):6195. doi: 10.1038/s41467-025-61472-z.
2
Low Levels of Neutralizing Antibodies Against SARS-CoV-2 KP.3.1.1 and XEC in Serum From Seniors in May 2024.2024年5月老年人血清中针对新冠病毒KP.3.1.1和XEC的中和抗体水平较低。
Influenza Other Respir Viruses. 2025 May;19(5):e70102. doi: 10.1111/irv.70102.
3
Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)亚变体KP.3.1.1和XEC的抗体逃避性
Cell Rep. 2025 Apr 22;44(4):115543. doi: 10.1016/j.celrep.2025.115543. Epub 2025 Apr 8.
4
Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.新型冠状病毒XEC变异株N端结构域糖基化突变在免疫逃逸、细胞间融合及刺突蛋白稳定性中的作用
J Virol. 2025 Apr 15;99(4):e0024225. doi: 10.1128/jvi.00242-25. Epub 2025 Mar 26.
5
Genetic Diversity and Spatiotemporal Distribution of SARS-CoV-2 Variants in Guinea: A Meta-Analysis of Sequence Data (2020-2023).几内亚新冠病毒变异株的遗传多样性与时空分布:序列数据的荟萃分析(2020 - 2023年)
Viruses. 2025 Jan 31;17(2):204. doi: 10.3390/v17020204.
6
SARS-CoV-2 XEC: A Genome-Based Survey.严重急性呼吸综合征冠状病毒2型XEC:一项基于基因组的调查。
Microorganisms. 2025 Jan 24;13(2):253. doi: 10.3390/microorganisms13020253.
7
Virological characteristics of the SARS-CoV-2 LP.8.1 variant.严重急性呼吸综合征冠状病毒2型LP.8.1变体的病毒学特征
Lancet Infect Dis. 2025 Apr;25(4):e193. doi: 10.1016/S1473-3099(25)00079-9. Epub 2025 Feb 10.
8
Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株LF.7.2.1、NP.1和LP.8.1的病毒学及抗原特性
Lancet Infect Dis. 2025 Mar;25(3):e128-e130. doi: 10.1016/S1473-3099(25)00015-5. Epub 2025 Jan 28.
9
Two Years of SARS-CoV-2 Omicron Genomic Evolution in Brazil (2022-2024): Subvariant Tracking and Assessment of Regional Sequencing Efforts.巴西两年的新冠病毒奥密克戎基因组进化研究(2022 - 2024年):亚变体追踪及区域测序工作评估
Viruses. 2025 Jan 4;17(1):64. doi: 10.3390/v17010064.
10
determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models.使用小鼠模型确定针对新冠病毒变异株的保护性抗体阈值
Emerg Microbes Infect. 2025 Dec;14(1):2459140. doi: 10.1080/22221751.2025.2459140. Epub 2025 Feb 7.